Skip to content
10-Q

Quarterly Report

PATHFINDER CELL THERAPY, INC.

0001213900-15-006016

← back to feed
Filed
Aug 13, 2015 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2015 · Jun 30, 2015 667.16M sh
Operating Cash Flow Q2 2015 · Jun 30, 2015 −$274K
Operating Cash Flow Q2 2015 · Jun 30, 2014 −$608K
Stockholders Equity Q2 2015 · Jun 30, 2015 −$6.44M
Stockholders Equity Q2 2015 · Dec 31, 2014 −$5.94M
Current Liabilities Q2 2015 · Jun 30, 2015 $6.49M
Current Liabilities Q2 2015 · Dec 31, 2014 $6.05M
Current Assets Q2 2015 · Jun 30, 2015 $18K
Current Assets Q2 2015 · Dec 31, 2014 $73K
Total Assets Q2 2015 · Jun 30, 2015 $49K
Total Assets Q2 2015 · Dec 31, 2014 $106K
Sga Expense Q2 2015 · Jun 30, 2015 $116K
Sga Expense Q2 2015 · Jun 30, 2015 $307K
Sga Expense Q2 2015 · Jun 30, 2014 $200K
Sga Expense Q2 2015 · Jun 30, 2014 $500K
Rd Expense Q2 2015 · Jun 30, 2015 $28K
Rd Expense Q2 2015 · Jun 30, 2015 $41K
Rd Expense Q2 2015 · Jun 30, 2014 $65K
Rd Expense Q2 2015 · Jun 30, 2014 $183K
Net Income Q2 2015 · Jun 30, 2015 −$222K
Net Income Q2 2015 · Jun 30, 2015 −$498K
Net Income Q2 2015 · Jun 30, 2014 −$332K
Net Income Q2 2015 · Jun 30, 2014 −$817K
Operating Income Q2 2015 · Jun 30, 2015 −$144K
Operating Income Q2 2015 · Jun 30, 2015 −$348K
Operating Income Q2 2015 · Jun 30, 2014 −$265K
Operating Income Q2 2015 · Jun 30, 2014 −$688K
Cash And Equivalents Q2 2015 · Dec 31, 2014 $26K
Cash And Equivalents Q2 2015 · Jun 30, 2014 $21K
Cash And Equivalents Q2 2015 · Dec 31, 2013 $44K